Financial Performance - Cumulative revenue for the first three quarters of 2025 is 2.826 billion, a decrease of 12.71% compared to the same period last year [2] - Single-quarter revenue for Q3 2025 is 956 million, down 13% year-on-year from 1.099 billion [3] - Cumulative net profit after deducting non-recurring items is 363 million, a decline of 30.3% from 521 million in the previous year [3] - Single-quarter net profit for Q3 2025 is 96 million, down approximately 21% from 123 million in Q2 2025 [3] - Gross margin for the first three quarters is approximately 62.3%, up from 54.6% in the same period last year [3] Asset and Liability Overview - Total assets as of the end of Q3 2025 are 7.263 billion, with net assets of 6.025 billion [3] - Asset-liability ratio is approximately 17.04% [3] Sales and Profit Decline Analysis - Sales revenue decline is attributed to factors such as centralized procurement, price fluctuations in raw materials, and intensified market competition [3] - Prices of raw materials have shown a downward trend, affecting both revenue and profit margins [3] - The company aims to enhance production efficiency and innovate to adapt to the changing market landscape [3] Sales Expense Increase - Increase in sales expenses is primarily due to the market introduction phase of several new products [4] - The company is preparing a professional sales team to support the commercialization of new products [4] R&D Strategy - The company has completed the consistency evaluation of existing products and is actively exploring new targets based on clinical needs [5] - Focus on innovative development, including steroid-based innovations and exploring new attractive products beyond steroid limitations [5] Export Situation - The company's export of formulation products is in its early stages, with limited sales primarily in the U.S. market [6] - The company is strategically planning its export products based on various factors including market demand and entry barriers [6] Market Performance by Product Category - Gynecological products generated 310 million in sales, down from 340 million last year, with a notable decrease in sales of progesterone capsules [7] - Respiratory products achieved 600 million in sales, a 15% increase year-on-year, while sales of tiotropium bromide inhalation powder declined by 32% [8] Company Collaboration - Italian Newchem company reported stable revenue of approximately 434 million in the first quarter, maintaining collaboration with Xianju [9] - The company is enhancing production processes and exploring new markets to support future growth [9] Product Approval Status - The company submitted a New Drug Application for Omecamtiv Mecarbil injection in September 2024, currently in the review process [10]

Core Viewpoint - The company has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed, with no significant omissions or misleading statements [2][10][12]. Financial Data Summary Major Financial Indicators - Prepayments increased by 179.68% compared to the beginning of the year, amounting to an increase of 56.24 million yuan, primarily due to increased contractual prepayments [3]. - Other receivables rose by 31.56%, increasing by 14.47 million yuan, mainly due to an increase in other temporary payments [3]. - Other current assets increased by 46.77%, up by 8.02 million yuan, attributed to an increase in retained tax amounts [3]. Balance Sheet Changes - Short-term borrowings surged by 1422.48%, increasing by 121.05 million yuan, mainly due to increased borrowings during the period [4]. - Notes payable increased by 295.34%, up by 65.93 million yuan, primarily due to increased use of notes payable for settling payments [4]. - Other payables rose by 73.58%, increasing by 134.45 million yuan, mainly due to the impact of payable dividends [4]. - Non-current liabilities due within one year increased by 486.42%, up by 95.65 million yuan, primarily due to an increase in long-term borrowings due within one year [4]. Profit and Loss Statement Changes - Financial expenses increased by 77.46% compared to the same period last year, rising by 18.07 million yuan, mainly due to reduced interest income [5]. - Investment income decreased by 196.07%, down by 25.00 million yuan, primarily due to the disposal of equity in the previous period [5]. - Asset disposal income increased by 6432.33%, up by 47.00 million yuan, attributed to asset transfers during the period [5]. Cash Flow Statement Changes - Tax refunds received increased by 236.45%, up by 3.05 million yuan, mainly due to increased export tax rebates [6]. - Cash paid for purchasing goods and services decreased by 39.07%, down by 335.90 million yuan, primarily due to reduced cash payments for purchases [6]. - Cash received from borrowings increased by 6480%, up by 324.00 million yuan, mainly due to increased borrowings during the period [6]. Shareholder Information - The total number of shareholders and the situation of the top ten shareholders have been reported, with no significant changes noted [7].

证券代码：002332 证券简称：仙琚制药 公告编号：2025-047 浙江仙琚制药股份有限公司 第八届监事会第十二次会议决议公告 会议以 7 票同意，0 票弃权，0 票反对，审议通过了《公司 2025 年第三季度 报告》。经审核，监事会认为：公司董事会编制和审核《公司 2025 年第三季度报 告》程序符合法律、行政法规和中国证监会的规定；报告内容真实、准确、完整 地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 特此公告。 浙江仙琚制药股份有限公司 监事会 2025 年 10 月 28 日 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）第八届监事会第十二次会 议通知已于2025年10月16日以电子邮件方式向公司全体监事发出，会议于2025 年 10 月 27 日上午以通讯方式召开。本次会议应参加监事 7 名，实际参加监事 7 名，会议由公司监事会主席吴天飞先生召集并主持。本次会议的召集、召开符合 《中华人民共和国公司法》和《公司章程》的有关规定。全体与会监事以记名投 票方式通过以下决议： ...

第八届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002332 证券简称：仙琚制药 公告编号：2025-046 浙江仙琚制药股份有限公司 特此公告。 浙江仙琚制药股份有限公司 董事会 2025 年 10 月 28 日 浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十七次会 议通知已于2025年10月16日以电子邮件方式向公司全体董事发出，会议于2025 年 10 月 27 日上午以通讯方式召开。本次会议应参加董事 9 名，实际参加董事 9 名，会议由公司董事长张宇松先生召集并主持。本次会议的召集、召开符合《中 华人民共和国公司法》和《公司章程》的有关规定。全体与会董事以记名投票方 式通过以下决议： 会议以 9 票同意，0 票弃权，0 票反对，审议通过了《公司 2025 年第三季度 报告》。 ...

浙江仙琚制药股份有限公司 2025 年第三季度报告 证券代码：002332 证券简称：仙琚制药 公告编号：2025-045 浙江仙琚制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 浙江仙琚制药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 减 | 年同期增减 | | | 营业收入（元） | 956,353,361.96 | -12.99 ...

Core Viewpoint - The report by Zhiyan Consulting highlights the growth and future trends in China's chemical pharmaceutical industry, indicating a steady increase in production and market dynamics from 2025 to 2031 [1]. Industry Summary - According to the National Bureau of Statistics, the production of chemical pharmaceutical raw materials in China reached 263,000 tons in August 2025, with a cumulative production of 2,477,000 tons from January to August 2025, reflecting a growth of 3.1% [1]. - The report provides insights into the supply and demand situation in the chemical pharmaceutical industry, projecting future trends and market conditions [1]. Company Summary - Listed companies in the report include Heng Rui Medicine, East China Medicine, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical, indicating a diverse range of players in the market [1]. - The report emphasizes the importance of industry research and consulting services in aiding investment decisions, showcasing Zhiyan Consulting's expertise in providing comprehensive industry solutions [1].

Core Viewpoint - The report by Zhiyan Consulting highlights the growth trends in China's chemical pharmaceutical industry, projecting a production increase in raw chemical drugs by 3.4% year-on-year in April 2025, with a cumulative growth of 3.9% from January to April 2025 [1] Industry Summary - In April 2025, China's production of raw chemical drugs reached 332,000 tons, marking a year-on-year increase of 3.4% [1] - The cumulative production of raw chemical drugs from January to April 2025 totaled 1,257,000 tons, reflecting a cumulative growth of 3.9% [1] - The report provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1] Company Summary - Listed companies in the report include Heng Rui Medicine, East China Pharmaceutical, Lijun Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive consulting services for investment decisions [1]

Core Viewpoint - Xianju Pharmaceutical stated that estradiol tablets are indicated for diseases related to estrogen deficiency and can also prevent osteoporosis [2] Group 1: Product Information - Estradiol tablets are used for conditions caused by estrogen deficiency [2] - The product can help in the prevention of osteoporosis [2] - Export of the formulation requires obtaining relevant product certification from foreign markets [2] Group 2: Usage Guidelines - Specific usage and dosage of prescription drugs should follow the advice of a physician [2]

10月16日，仙琚制药跌0.20%，成交额1.09亿元。两融数据显示，当日仙琚制药获融资买入额1311.19万 元，融资偿还1604.82万元，融资净买入-293.63万元。截至10月16日，仙琚制药融资融券余额合计5.67 亿元。 截至9月30日，仙琚制药股东户数5.00万，较上期增加0.00%；人均流通股19691股，较上期增加0.00%。 2025年1月-6月，仙琚制药实现营业收入18.69亿元，同比减少12.56%；归母净利润3.08亿元，同比减少 9.26%。 分红方面，仙琚制药A股上市后累计派现20.31亿元。近三年，累计派现9.89亿元。 机构持仓方面，截止2025年6月30日，仙琚制药十大流通股东中，南方中证1000ETF（512100）位居第 九大流通股东，持股733.51万股，相比上期增加140.94万股。香港中央结算有限公司、兴全合丰三年持 有混合（009556）退出十大流通股东之列。 责任编辑：小浪快报 融资方面，仙琚制药当日融资买入1311.19万元。当前融资余额5.65亿元，占流通市值的5.81%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，仙琚制药10月16日融券偿 ...

Group 1 - The company Xianju Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payment of 1.00 RMB per 10 shares to all shareholders [1] - The total number of shares used as the basis for the dividend distribution is 989,204,866 shares [1] - The record date for the dividend is set for October 21, 2025, and the ex-dividend date is October 22, 2025 [1]